Interrelation between ofsystemic inflammation factors and cardiovascular calcification factors in patients of chronic kidney disease 5D stage

BACKGROUND. The role of inflammation and uremic intoxication in the development and progression of bone mineral dis­orders, including cardiovascular calcification, has been actively studied over the past decades. PATIENTS AND METHODS. A single-stage, cohort study of 85 patients with stage 5D CKD treated with programmatic hemodialysis was conducted. The blood concentrations of interleukin-3 (IL-3) and interleukin-6 (IL-6) were determined using the enzyme immunoassay, the level of fibrinogen - using the Rutberg method, and the level of p2-microglobulins - using the nephelometric method. The blood leu­kocyte shift index (ISLC) and the Glasgow Prognostic Score (GPS) risk index for systemic inflammation were also calculated, taking into account the level of C-reactive protein (CRP) and blood albumin. The presence of valvular calcification, its severity, and calcification of the abdominal aortic wall was recorded. Statistical analysis was performed using the program STATISTICA 12.6 ("StatSoft", USA). THE AIM: to evaluate the relationship between factors of systemic inflammation and cardiovascular cal­cification in patients with stage 5D chronic kidney disease. RESULTS. The risk of detecting calcification of the aorta and heart valves was influenced by the pro-inflammatory cytokines IL-3 and IL-6, as well as ISLK and GPS. However, inflammatory fac­tors such as fibrinogen, p2-microglobulin, and CRP levels in the blood did not show a statistically significant effect. In the case when the predicted parameter was chosen not friendly calcification, but the presence of any of its components, the predictive significance of IL-3 decreased, but IL-6 remained. The 20% risk threshold was exceeded at IL-6 values of more than 33 pg/ml. The effect of ISLC on the probability of detection of calcification was shown both about friendly calcification and concerning isolated calcification of the aorta or valves. CONCLUSION. It was found that among the studied factors of inflammation, IL-6, ILK, and IL-3 demonstrate a relationship with the processes of cardiovascular calcification, GPS-only in relation to friendly calcification. Nomograms have been developed that allow predicting the detection of cardiovascular calcification in dialysis patients, depending on the state of the inflammatory circuit.

1. Bruck К, Stel VS, Gambaro GJ et al. CKD Prevalence Var­ies across the European General Population. Am Soc Nephrol 2016;27(7):2135-2147

2. Hill NR, Fatoba ST, Oke JL et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One 2016;11(7):0158765

3. Rumyantcev AS, Rafrafi H, Galkina OV. Calcification of the aortic valve in patients on program hemodialysis. Nephrology (Saint-Petersburg) 2018;22(4):90-95 (In Russ.). https://doi.org/10.24884/1561-6274-2018-22-4-90-95

4. Brandenburg VM, Verhulst A, Babler A et al. Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it! Nephr Dial Transpl 2019;34(3):408-414

5. Ganidagli B, Nacar H,YildyzYS et al. The relationship be­tween serum osteopontin and FGF-23 levels with valvular calcifica­tion in hemodialysis patients. Clin Nephr 2019;91(1):9-17

6. Uhlin F, Fernstrom A, Knopen MHJet al. Long-term follow- up of biomarkers of vascular calcification after switch from tradi­tional hemodialysis to online hemodiafiltration. Scand J Clin Lab Invest 2019;18:1-9

7. Covic A, Vervloet M, Massy ZAetal. Bone and mineral dis­orders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes Endocrinol 2018;6(4):319-331

8. Sato M, HanafusaN, Kawaguchi Hetal. Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients. Kidney Blood Press Res 2018;43(3):1023-1033

9. Anders HJ, Suarez-Alvarez B, Grigorescu M et al. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney dis­ease independent from IL-1-mediated tissue injury. Kidney Int 2018;93(3):656-669

10. Benz K, Hilgers KF, Daniel C, Amann K. Vascular Calcifi­cation in Chronic Kidney Disease: The Role of Inflammation. IntJ Nephrol 2018;2018:4310379

11. Mutluay R, Konca Degertekin C, Ijikta? Sayilar E et al. Serum fetuin-A is associated with the components of MIAC (mal­nutrition, inflammation, atherosclerosis, calcification) syndrome in different stages of chronic kidney disease. Turk J Med Sci 2019;49(1):327-335

12. Donate-Correa J, Henrfquez-Palop F, Martin-Nffiez Eet al. Anti-inflammatory profile of paricalcitol in kidney transplant recipients. Nefrologia 2017;37(6):622-629. doi: 10.1016/j. nefro.2017.03.028

13. BirueteA, Hill Gallant KM, LindemannSRetal. Phosphate Binders and Nonphosphate Effects in the Gastrointestinal Tract. J ofRenalNutrition 2019;4:5-7

14. Maraj M, Kusnierz-Cabala B, Dumnicka P, et al. Malnu­trition, Inflammation, Atherosclerosis Syndrome (MIA) and Diet Recommendations among End-Stage Renal Disease Patients Treated with Maintenance Hemodialysis. Nutrients. 2018;10(1):69. Published 2018Jan11. doi:10.3390/nu10010069

15. KDIGO Clinical Practice Guideline Update for the Diag­nosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2017;7(1):1-59

16. Honkanen E, Kauppila L, Wikstrom В etal. Abdominal aortic calcification in dialisis patients: results of the CORD study. Nephr Dial Transpl 2008;23:4009-4016